Literature DB >> 7955816

Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity.

B A Hamelin1, K Xu, F Vallé, L Manseau, M Richer, M LeBel.   

Abstract

STUDY
OBJECTIVE: To characterize the activities of the P450 mixed-function oxidase CYP1A2 as well as the cytosolic enzymes N-acetyltransferase and xanthine oxidase using caffeine as a probe in children with cystic fibrosis compared to age-matched healthy control subjects.
METHODS: After administration of caffeine (cola beverage) to 12 children with cystic fibrosis (age range, 5 to 11 years) and 12 healthy control subjects (age range, 5 to 12 years), urine was collected for 4 hours. Caffeine metabolites were determined by HPLC, and urinary caffeine metabolite ratios were computed to determine liver enzyme activities. In addition, a blood sample was used to detect cystic fibrosis mutant alleles by polymerase chain reaction.
RESULTS: The indexes for CYP1A2, N-acetyltransferase, and 8-hydroxylation were similar in both groups of subjects. In contrast, there was a significant difference in the frequency distribution of the xanthine oxidase activity between the two groups. Nine of 12 patients with cystic fibrosis but only one of 12 healthy volunteers had xanthine oxidase activities above 0.42 (Kolmogorov-Smirnov two-sample test, p < 0.01).
CONCLUSIONS: Differences in xanthine oxidase may have clinical implications with regard to interindividual variation in xenobiotic biotransformation and the exposure to lung tissue-damaging oxygen radicals. Hepatic enzyme activities appear to be selectively altered in patients with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955816     DOI: 10.1038/clpt.1994.173

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 2.  The role of non-P450 enzymes in drug oxidation.

Authors:  C Beedham
Journal:  Pharm World Sci       Date:  1997-12

3.  Enhanced drug metabolism in young children with cystic fibrosis.

Authors:  A C Parker; P Pritchard; T Preston; R L Smyth; I Choonara
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

4.  A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.

Authors:  Ashish Sharma; Sylvie Pilote; Pierre M Bélanger; Marie Arsenault; Bettina A Hamelin
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

5.  Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection.

Authors:  Brian J Day; Anna M van Heeckeren; Elysia Min; Leonard W Velsor
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

Review 6.  Altered intravenous drug disposition in people living with cystic fibrosis: A meta-analysis integrating top-down and bottom-up data.

Authors:  Pieter-Jan De Sutter; Maxime Van Haeverbeke; Eva Van Braeckel; Stephanie Van Biervliet; Jan Van Bocxlaer; An Vermeulen; Elke Gasthuys
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.